Zinc in multiple sclerosis
Bredholt, Mikkel; Fredriksen, Jette Lautrup

Published in:
ASN Neuro

DOI:
10.1177/1759091416651511

Publication date:
2016

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Bredholt, M., & Fredriksen, J. L. (2016). Zinc in multiple sclerosis: A systematic review and meta-analysis. DOI: 10.1177/1759091416651511
Zinc in Multiple Sclerosis: A Systematic Review and Meta-Analysis

Mikkel Bredholt¹ and Jette Lautrup Frederiksen¹

Abstract
In the last 35 years, zinc (Zn) has been examined for its potential role in the disease multiple sclerosis (MS). This review gives an overview of the possible role of Zn in the pathogenesis of MS as well as a meta-analysis of studies having measured Zn in serum or plasma in patients with MS. Searching the databases PubMed and EMBASE as well as going through reference lists in included articles 24 studies were found measuring Zn in patients with MS. Of these, 13 met inclusion criteria and were included in the meta-analysis. The result of the meta-analysis shows a reduction in serum or plasma Zn levels in patients with MS with a 95% CI of \([-3.66, -0.93]\) and a \(p\) value of .001 for the difference in Zn concentration in \(\mu\)M. One of six studies measuring cerebrospinal fluid, Zn levels found a significant increase in patients with MS with controls. The studies measuring whole blood and erythrocyte Zn levels found up to several times higher levels of Zn in patients with MS compared with healthy controls with decreasing levels during attacks in relapsing-remitting MS patients. Future studies measuring serum or plasma Zn are encouraged to analyze their data through homogenous MS patient subgroups on especially age, sex, and disease subtype since the difference in serum or plasma Zn in these subgroups have been found to be significantly different. It is hypothesized that local alterations of Zn may be actively involved in the pathogenesis of MS.

Keywords
multiple sclerosis, zinc, meta-analysis, serum, plasma, matrix metalloproteinases

Received January 11, 2016; Received revised February 9, 2016; Accepted for publication April 19, 2016

Introduction
Multiple sclerosis (MS) is categorized as an autoimmune disease and is potentially one of the most common causes of neurological disability in young adults. The disease can generally be divided into three clinical subtypes: relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), and primary progressive MS (PPMS), although studies question the homogeneity of the disease with especially PPMS having a different clinical course and a seemingly different pathogenesis (Foong et al., 2000; Lassmann et al., 2001). Formation of the sclerotic plaques of which the disease gets its name represents the end stage of a process involving inflammation, demyelination and remyelination, oligodendrocyt depletion, and astrogliosis as well as neuronal and axonal degeneration. The inflammation may impede the proper propagation in three ways: inflammatory mediators directly impede conduction in intact axons, the demyelination of axons by microglia thereby compromising the ability of proper conduction of the axon, or axonal transection (Compston and Coles, 2008). The etiology of the disease is not known though it is clear that it is caused by a complex interplay between genes and environment (Sadovnick and Ebers, 1993). The strongest genetic associations have been found to be in the major histocompatibility complex with HLA-DRB1 to have the strongest effect (Patsopoulos et al., 2013). Other genes have been identified as well, with Zn-ion binding genes involved in the expression of IFN-γ being able to predict the clinical outcome in RRMS patients with 88.9% accuracy (Achiron et al., 2007).

¹Department of Neurology, Rigshospitalet – Glostrup, University of Copenhagen, Glostrup, Denmark

Corresponding Author:
Mikkel Bredholt, Department of Neurology, Rigshospitalet – Glostrup, University of Copenhagen, Nordre Ringvej 57, Glostrup 2600, Denmark.
Email: mikkelbredholt@hotmail.com
Zinc

Zn is an essential trace element for all organisms, and Zn level alterations have consequences on particularly the nervous, the reproductive and the immune system. Being a cofactor of more than 300 enzymes including matrix metalloproteinases (MMPs) and a component of an even greater amount of proteins including Myelin Basic Protein, Zn emphasizes its important role in human health (Vallee and Falchuk, 1993; Berlet et al., 1994). Zn’s plasma concentration is 12 to 16 μM and is nearly completely protein-bound with 80% bound to albumin and 20% bound to α2-macroglobulin (Scott and Bradwell, 1983). Zn is an abundant metal in the brain and is mainly found in presynaptic vesicles in neurons. With Zn deficiency being able to induce apoptosis in neural cells as well as high levels of Zn being neurotoxic, it is clear that efficient Zn homeostasis in the brain is important (Yokoyama et al., 1986; Adamo et al., 2010).

Zn and the immune system. Zn deficiency decreases several functions in the immune system including peripheral T-cell count, T-helper cell function, cytotoxic T-cell activity, NK-cell activity, and macrophage and neutrophil functions (Rink and Gabriel, 2000). Even though these effects seem contradictory of Zn deficiency being involved in the exacerbation of MS as an autoimmune disease, a study by Kitamura et al. (2006) showed that the intracellular reduction of Zn is an activator of dendritic cell maturation resulting in increased cell-surface expression of MHC and costimulatory molecules, potentially resulting in unwanted activation of T-cells and T-cell mediated autoimmunity. Elevation of Zn alone can induce the expression of the high-affinity receptor for IL-2, important for the proliferation and differentiation of CD4+ and CD8+ lymphocytes to efferent cells, as well as being able to trigger microglia activation, the resident immune cell of the CNS important in the pathogenesis of MS (Tanaka, 1989; Higashi et al., 2011).

Zn and MMPs. MMPs are a group of proteases all dependent of Zn for their proteolytic activity. They are involved in remodeling of the extracellular matrix and modifying cell-matrix interactions (Murphy and Nagase, 2008). Their proteolytic substrates include myelin basic protein, components of the blood–brain barrier (BBB), and neural/glial antigen 2 (NG2), important for proper remyelination in the CNS, giving them a potential important role in both the pathogenesis of MS as well as in the development of new treatments for MS (Chandler et al., 1995; Larsen et al., 2003; Ram et al., 2006). Studies measuring MMP levels in patients with MS have shown that several MMPs are altered (Bar-Or et al., 2003). A study by Kanesaka et al. (2006) showed that serum MMP-3 was significantly higher within 1 month before a relapse compared with the remission-phase serum levels of RRMS patients, suggesting a role in disease exacerbation through increased disruption of the BBB. The studies implicate an important role of especially MMP-9 in MS with results showing increased serum and cerebrospinal fluid (CSF) levels of MMP-9 in patients with MS compared with healthy controls (HCs) and increased MMP-9 CSF levels in RRMS patients during active disease compared with stable RRMS patients (Liuzzi et al., 2002). The involvement of MMP-9 in MS is further emphasized in a study by Correale and Bassani (2003) showing that MMP-9 levels in clinical isolated syndrome (CIS) patients that developed clinically definite MS was significantly higher than in those who did not.

The altered levels of MMPs may influence MS pathogenesis in several ways. First of MMPs may mediate migration of autoreactive lymphocytes across the BBB by their proteolytic degradation of the subendothelial basement membrane. This is shown by Leppers et al. (1995) in an in vitro model of the BBB with increasing levels of MMPs to result in increased migration of T-cells. Second, MMPs may contribute to myelin breakdown because of their proteolytic activity against myelin basic protein as well as contribute to epitope spreading of these. Even though MMP levels are highest during exacerbation of MS, it might also be important in the remission of the disease, as Larsen et al. (2003) showed by impairing remyelination in mice lacking MMP-9 because of their failure to clear NG2, a proteoglycan retarding the maturation and differentiation of oligodendrocytes. With all of the MMPs being Zn dependent for their proteolytic activity, local alterations in Zn level will most likely influence the effect of MMPs.

Zn altering therapy. With Zn’s role in MS yet to be fully understood, it is still unclear whether altering Zn levels is helpful in inhibiting disease exacerbation. Studies of Zn supplementation have shown reduced T-cell activation and proliferation thereby being a promising approach in a future therapeutic manner (Stoye et al., 2012). Although a recent study showed no improvements of neurological signs in patients with MS compared with the placebo group after 12 weeks of Zn supplementation (Salari et al., 2015), another approach by Choi et al. (2013) with redistributing Zn in the body with Clioquinol (a Copper or Zn chelator) has shown promising results in the animal model of MS: Experimental Autoimmune Encephalitis (EAE). The study showed suppression of demyelination, reduced infiltration of encephalitogenic immune cells, inhibited BBB disruption, reduced MMP-9 activation and reduced clinical score of EAE after treatment with Clioquinol.

With the study by Wong et al. (1980) showing significantly reduced plasma Zn levels in patients with MS, studies have been performed since then studying Zn levels in patients with MS to unravel this potential role of Zn in the etiology or pathogenesis of MS.

As the amount of studies studying Zn levels in patients with MS accumulate and studies, with especially serum or plasma Zn levels showing heterogeneity in their results,
a systematic review and a meta-analysis are performed to create an overview of the published results of Zn measuring studies in patients with MS.

**Methods**

**Search Strategy and Inclusion Criteria**

The literature-search was done in PubMed and EMBASE. The search profile for PubMed consisted of “Zinc AND ‘multiple sclerosis’” giving 133 hits and “Zinc AND ‘optic neuritis’” giving 14 hits with no overlap. The search profile for EMBASE consisted of “Zinc AND *multiple sclerosis” giving 141 hits and “Zinc AND *optic neuritis” giving 3 hits with no overlap. For both search profiles, all titles got examined and abstracts read of those maybe being relevant. Reference lists of retrieved studies were searched for additional reports. Inclusion criteria were studies having measured Zn levels in patients with MS.

**Meta-Analysis Inclusion Criteria**

Inclusion criteria for studies in the meta-analysis were studies with results on serum or plasma Zn levels given in mean ± SD or SEM. With studies only giving results of subgroups, the weighted grand mean of the patients with MS included in the study was calculated, and the composite SD was found by analysis of variance.

**Meta-Analysis Statistical Method**

Mean difference as well as 95% confidence intervals (CIs) were calculated using a random effects model instead of the fixed effect model, as heterogeneity between studies are expected. Random effect models assume and account for variable underlying effects in estimates of uncertainty, including both within-study and between-studies variance (Borenstein et al., 2009). The effect sizes were calculated with Review Manager (RevMan) [Computer program] Version 5.3., Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

**Results**

Of the 291 hits and of the reference lists in retrieved studies, 24 articles were found to study Zn levels in patients with MS, of which 19 had measured serum or plasma Zn levels and 6 had measured CSF Zn levels. A total of 11 studies were found to study other parameters of Zn or having data on subgroup analysis on Zn levels. The results of the 19 studies measuring serum or plasma Zn levels in patients with MS are summarized in Table 1. The results of the six studies measuring CSF Zn levels in patients with MS are summarized in Table 2, and the conclusions of the studies measuring other parameters or subgroup analyses on Zn levels are reported in Table 3. Results given in other units were converted to μmol/L with (Zn = 65.38 g/mol) (Wieser Michael et al., 2013) and results given with SEM were converted back to SD. It was found by Foley et al. (1968) that plasma Zn was 16% higher than in serum, although later studies have shown no significant or only very little difference between serum and plasma Zn concentrations, therefore, making them comparable (Kosman and Henkin, 1979; Kasperek et al., 1981; Külerich et al., 1981; Chen et al., 1986).

**Meta-Analysis**

Of the 19 studies measuring serum or plasma Zn levels in patients with MS, 13 studies met inclusion criteria. The results of the meta-analysis is given in forest plot format in Figure 1 showing a significant difference in serum or plasma Zn levels in patients with MS versus HCs with a 95% CI of [−3.66, −0.93] and p = .001. An I² value on 97% shows high heterogeneity in the meta-analysis.

**Discussion**

The present meta-analysis of studies measuring serum or plasma Zn levels in MS reports a significant reduction in overall serum or plasma Zn levels in patients with MS, with studies reporting both lowered, no difference and increased serum or plasma Zn levels. Most of the studies included were in the non-significant range.

The great variance in the outcome of the studies might be explained by the heterogeneity of the serum or plasma Zn levels in patients with MS. The studies by Wong et al. (1980) and Palm and Hallmans (1982) show that the decrease in serum or plasma Zn with age in patients with MS does not correlate with the higher decrease seen in HCs with age. Studies including mostly old patients with MS may find no significant difference between MS and HCs even though it is possible that the younger patients with MS would show a significant difference. Therefore, it is not only enough for future studies to match patients with MS on age but also to be aware that a high mean age of patients with MS in the study might obscure a greater significant difference between younger patients with MS and HCs.

The study by Palm and Hallmans (1982) shows that the difference in correlation of decreasing serum or plasma Zn level with age between patients with MS and HCs is only found in males, as well as disease stage and degree of malignancy only having significant differences in Zn levels in male patients with MS. Therefore, some of the results showing no difference in serum or plasma Zn levels might be because of the low men or female MS patient ratio found in most of the studies.
the prevalence ratio of female versus men affected by MS being more than two to one, studies randomly selecting participants out of a MS population might find no significant results even though one is present in the male population of the participants. The results of Palm and Hallmans (1982) and Ghazavi et al. (2012) study not only emphasize the importance of keeping results between genders separated but also that the different subtypes of MS might have different alterations in serum or plasma Zn. Only the slowly progressive subgroup had significantly lowered Zn level in the study done by Palm and Hallmans and in the study done by Ghazavi et al., the patients with SPMS had significantly lowered Zn levels compared with the patients with RRMS. Future studies on serum or plasma Zn should, therefore, have in mind that uncritical mixing of patients with MS in studies on age, sex, disease subtype, duration of disease, and degree of disability might conceal a greater significant difference.

| Study                      | Body fluid | MS (N) | HC (N) | Mean ± SD MS | Mean ± SD HC | p       | Conclusion                                      |
|----------------------------|------------|--------|--------|---------------|--------------|---------|-------------------------------------------------|
| Wong et al. (1980)         | Plasma     | 26     | 39     | n/a          | n/a          | <.0001  | Significantly lowered in MS (M + F) if age < 50 years |
| Weismann et al. (1982)     | Plasma     | 10     | n/a    | 13 ± n/a     | n/a          | .01     | Correlation between low plasma Zn and low albumin in MS |
| Palm and Hallmans (1982)   | Serum      | M: 21  | M: 21  | 13.0 ± 1.9   | 14.8 ± 1.6   | <.001   | Significantly lowered in MS (M + F)               |
| Dore-Duffy et al. (1983)   | Plasma     | M: 18  | M: 30  | 14.8 ± 3.2   | 12.5 ± 1.8   | <.01    | Only significantly higher in MS males             |
| Ho et al. (1986)           | Plasma     | 45     | 23     | 13.6 ± 3.1   | 13.5 ± 1.5   | NS      | NS for MS (M + F)                                |
| Kapaki et al. (1989)       | Serum      | 15     | 28     | 15.8 ± 2.1   | 16.8 ± 2.9   | NS      | NS                                              |
| Smith et al. (1989)        | Plasma     | 14     | 33     | 15.7 ± 3.0   | 15.3 ± 0.1   | NS      | NS                                              |
| Forte et al. (2005)        | Plasma     | 60     | 60     | 91.7 ± 22.8  | 100.6 ± 15.5 | ≤.05    | Significantly lowered in MS                      |
| Alimonti et al. (2007)     | Serum      | M: 18  | M: 30  | 5.0 ± 3.3    | 20.2 ± 6.1   | n/a     | Significantly lowered in MS (M + F)              |
| Masoud and Fakharian (2007) | Serum      | M: 7   | M: 7   | 12.0 ± 1.6   | 16.7 ± 1.6   | <.0001  | Significantly lowered in MS (M + F)              |
| Gellein et al. (2008)      | Plasma     | 9      | 16     | 5.1 ± 0.7    | 5.2 ± 0.9    | NS      | NS                                              |
| Harbige et al. (2011)      | Plasma     | 21     | 9      | 13.5 ± 2.5   | 13.1 ± 2.0   | NS      | NS                                              |
| Ghazavi et al. (2012)      | Serum      | M: 17  | M: 22  | 5.0 ± 3.3    | 20.2 ± 6.1   | n/a     | Significantly lowered in MS                      |
| Al-Zubaidi (2012)          | Serum      | 32     | 32     | 16.3 ± 3.3   | 23.0 ± 0.5   | <.0001  | Significantly lowered in MS                      |
| Nasrabi et al. (2012)      | Plasma     | 40     | 20     | n/a          | n/a          | NS      | NS                                              |
| Sedighi et al. (2013)      | Serum      | 58     | 39     | 36.7 ± n/a   | 40.9 ± n/a   | .249    | NS                                              |
| Kazmierczak et al. (2014)  | Plasma     | 11     | 38     | n/a          | n/a          | .8      | NS                                              |
| Giacoppi et al. (2014)     | Plasma     | 41     | 23     | 40.0 ± 9.6   | 43.0 ± 8.7   | NS      | NS                                              |
| Ghereishi et al. (2015)    | Serum      | 50     | 50     | 1.1 ± 0.06   | 0.7 ± 0.07   | <.005   | Significantly higher in MS                       |

Note. Mean and SD are given in μM. Different units have been converted to μM with (Zn = 65.38 g/mol), and SEM has been converted to SD. n/a = data not available; M = males; F = females; T = total; NS = non-significant; HC = Healthy controls.

*Unit of measurement not available.
in subgroups of the study. It was examined whether it was possible to analyze the correlation between Zn levels and MS in regard to age or sex of patients and HC, although too few studies had their results presented in a way for this to be possible.

Not all studies included in the meta-analysis mentioned the proper precautions done to prevent the influence of the many confounders in serum or plasma Zn level analysis. As shown by Rea (1989), serum Zn levels are dependent on age and sex, though sex and age matching was not mentioned in 5 out of the 13 studies included (Kapaki et al., 1989; Smith et al., 1989; Gellein et al., 2008; Harbige et al., 2011; Giacoppo et al., 2014). As different medication here including Prednisolone, INF-ß1 a-treatment and oral contraceptives alter serum or plasma Zn levels, treatment with these should be paused before blood sampling in both patients and HCs or be an exclusion criterion (Briggs et al., 1971; Fallah et al., 2009; Al-Zubaidi, 2012). Precautions done against the possible confounding factor of medication in patients and HCs were only mentioned in 7 out of the 13 studies included (Palm and Hallmans, 1982; Dore-Duffy et al., 1983; Ho et al., 1986; Kapaki et al., 1989; Forte et al., 2005; Al-Zubaidi, 2012; Ghazavi et al., 2012). The confounders mentioned so far are the most important in regard to the meta-analysis. The differences in the procedure of blood sampling and Zn analysis will not have a great impact on the result of the meta-analysis as long as the procedure has been the same between patients with MS and HCs and will mostly increase the heterogeneity between the studies. This is because of the use of the random effects model that also assumes and accounts for the regional differences in Zn levels (Iyengar, 1987). This is also the reason why the results of Forte et al. (2005), Gellein et al. (2008), Giacoppo et al. (2014), and Goreishi et al. (2015) were included, even though their results of plasma Zn are very different compared with the other studies. The low levels of serum or plasma Zn recorded in Gellein et al. and Goreishi et al. should result in severe Zn deficiency symptoms in both patients and HCs. Since the authors does not mention any reports of Zn deficiency as well as results in the four studies report Zn concentrations in the same levels for both patients and HCs, it is assumed that the low levels is a consequence of the analysis used in assessing the Zn concentration. It should be noted that the measuring of serum or plasma Zn levels includes many confounders here including circadian and postprandial fluctuations (Markowitz et al., 1985; Wallock et al., 1993) as well as being prone to contamination through hemolysis in blood samples and prolonged stasis while the blood sample is taken (Küllerich et al., 1980). Information about precautions against these confounders are lacking in most studies.

As most of the studies included reported no significant difference in serum or plasma Zn levels in patients with MS, the risk of publication bias to have an influence on the outcome of the meta-analysis is assumed to be low.

Of the six studies measuring CSF Zn levels, the study by Linke et al. (1977) found a significant increase, though none of the later studies could find a significant difference between patients with MS and controls. It is hard to

Table 2. Cerebrospinal Fluid Zinc in Multiple Sclerosis Versus Controls.

| Study                  | Body fluid | MS (N) | C (N) | Mean ± SD | Mean ± SD |
|------------------------|------------|--------|-------|-----------|-----------|
|                        |            |        |       | MS        | HC        |
|                        |            |        |       | p         | Conclusion |
| Linke et al. (1977)    | CSF        | 40     | 24a   | 3.12 ± 2.20 | 1.12 ± 0.66 | <.001 | Significantly higher in MS. |
| Palm and Hallmans (1982)| CSF       | M: 11  | M: 11b| 0.14 ± 0.03 | 0.17 ± 0.05 | NS    | NS   |
| Ho et al. (1986)       | CSF        | F: 18  | F: 18p| 0.15 ± 0.06 | 0.16 ± 0.04 | NS    | NS   |
| Kapaki et al. (1989)   | CSF        | 15     | 28d   | 0.53 ± 0.30 | 0.53 ± 0.08 | NS    | NS   |
| Melo et al. (2003)     | CSF        | 18     | 19e   | 0.29 ± 0.13 | 0.36 ± 0.21 | NS    | NS   |
| Gellein et al. (2008)  | CSF        | 9      | 16f   | 0.33 ± 0.09 | 0.38 ± 0.15 | NS    | NS   |

Note. Mean and SD are given in µM. Different units have been converted to µM (Zn = 65.38 g/mol), and SEM has been converted to SD. M = males; F = females; T = total; NS = non-significant; C = controls; Active = during attack.

*Patients with which cerebral disease has been excluded and with no deviation from standard levels.

bCSF samples from 18 HCs and the rest from patients with psychoneurosis, tension headache, and other pain syndromes in whom neurological examination failed to define an organic CNS lesion.

cPatients with other neurological diseases as Guillain-Barre disease, myasthenia gravis, central nervous system lupus erythematosus, bacterial meningitis, herpes encephalitis, amyotrophic lateral sclerosis, and pseudotumor cerebri.

dPatients cleared for neurological disease and with no sign of infection, liver disease, renal disease, tuberculosis, or alcoholism.

*Patients with no known neurological disorder or deficit.
Table 3. Other Parameters or Subgroup Analyses.

| Study                  | Parameter                                      | MS Total | HC Total | p     | Conclusion                                                                 |
|------------------------|------------------------------------------------|----------|----------|-------|-----------------------------------------------------------------------------|
| Wong et al. (1980)     | Plasma Zn and clinical classification of MS    | 26       | n/a      | NS    | No correlation between plasma Zn level and clinical classification of disease. |
| Palm and Hallmans (1982)| Serum Zn and disease stage (exacerbation, remission/steady state, slowly progressive) compared with HCs. | 50       | 50       | <.001 | Serum Zn only significantly lowered in males with slowly progressive MS compared with HCs. |
|                        | Serum Zn and degree of malignancy of MS        |          |          | <.001 | Serum Zn only significantly lowered in males with a malignancy score between 1 and 8 (>7 years duration, moderate/severe disability) |
| Rieder et al. (1983)   | Whole blood Zn                                 | 119      | 35       | <.01  | Significantly higher whole blood Zn in MS compared with HCs.               |
|                        | Whole blood Zn in male vs female MS cases      |          |          | <.05  | Significantly higher whole blood Zn in male MS cases compared with female MS cases. |
|                        | Whole blood Zn and disease MS subtype          |          |          | .02   | Significantly higher whole blood Zn in relapsing cases compared with chronic cases. |
| Dore-Duffy et al. (1983)| RBC bound Zn                                   | 68       | 60       | <.05  | RBC bound Zn significantly higher in MS compared with HCs.               |
|                        | α2-macroglobulin bound Zn                     |          |          | <.01  | α2-macroglobulin bound Zn significantly lowered in MS compared with HCs. |
| Ho et al. (1986)       | Whole blood Zn                                 | 45       | 23       | <.01  | Whole blood Zn significantly higher in MS compared with HCs.               |
|                        | RBC bound Zn                                   |          |          | <.01  | RBC bound Zn significantly higher in MS compared with HCs.               |
|                        | Zn in ghost material of RBC membranes          |          |          | <.01  | Zn in RBC ghost significantly higher in MS and associated with the lipid-soluble fraction. |
| Williams et al. (1988) | RBC bound Zn and disease activity              | 20       |          | <.05  | RBC bound Zn significantly lower in exacerbating MS                         |
| Smith et al. (1989)    | Plasma Zn and pressure sores                   | 27       | 33       | NS    | No significant difference between MS and HCs, but RBC bound Zn tended to be higher in MS. |
|                        | Steroid treatment and Zn levels                |          |          | NS    | No significant difference between steroid treated patients with MS and HCs, but serum and RBC Zn tended to be lower in MS. |
| Mauch et al. (1995)    | Whole blood Zn                                 | 67       | 62       | NS    | Near identical whole blood Zn levels in MS and HCs.                       |
| Gellein et al. (2008)  | Whole blood Zn                                 | 9        | 16       | NS    | No significant difference between MS and HCs, but whole blood Zn tended to be higher in MS. |
| Ghazavi et al. (2012)  | Serum Zn and disease MS subtype                | 60       |          | .009  | Significantly lowered serum Zn in secondary progressive MS compared with RRMS. |
| Al-Zubaidi (2012)      | Methylprednisolone treatment and serum Zn      | 96       |          | <.0001 | Significantly lowered serum Zn in treated patients with MS compared with non-treated patients with MS. |
|                        | Interferon-ß1 treatments and serum Zn         |          |          | <.0001| Significantly higher serum Zn in treated patients with MS compared with non-treated patients with MS. |

Note. Degree of malignancy = Duration score × Disability level. Duration score: 1–3 years = 5, 4–6 years = 4, 7–9 years = 3, 10–15 years = 2, > 15 = 1. Disability level: mild = 2, moderate = 3, severe = 4. n/a = no data available, NS = non-significant, HC = healthy controls, RBC = red blood cells.
conclude anything on those studies since the high SD in most of the studies report big variance between the measurements and combined with the small number of participants it is highly unlikely to be able to find a statistical difference. The big SD and the variance in Zn levels between the studies may be explained be the small amount of Zn present in CSF fluid, making the measurements very susceptible to contamination during the analysis. It should be noted although that of the five studies done after Linke et al., the mean were in MS found either to be the same or slightly lower than in the control group.

Beside the significant decrease in plasma or serum Zn levels in patients with MS compared with HCs other interesting findings in regard to Zn’s potential influence on MS pathogenesis so far is the alterations of whole blood Zn of patients with MS as reported by several studies as well as the increase in RBC Zn. Whole blood Zn was found to be higher in patients with MS, with male patients with MS having significantly higher levels compared with female patients and relapsing cases having increased levels as well compared with chronic cases as shown by Rieder et al. (1983). Some of the explanation for this increase is elaborated in the studies by Dore-Duffy et al. (1983) and Ho et al. (1986) showing increased amount of Zn in the lipid-soluble fraction of RBC membranes with results showing up to 3 to 4 times higher Zn in membranes of RBCs in patients with MS as well as an increased amount of Zn bound to α2-macroglobulin. With no difference in plasma Zn as well as cytoplasmic RBC Zn, they suggest that patients with MS have altered compartmentalization of Zn.

With the study by Ho et al. (1986) showing a dramatic reduction of these Zn levels during the exacerbation of an MS attack and slowly increasing Zn levels during the remission, together with the promising therapeutic effect on EAE by altering Zn levels with Clioquinol, alterations in local Zn levels may play an important role in the pathogenesis of MS. Future studies should examine whether the alteration in compartmentalization in Zn is only present in RBC or is also present in lymphocytes or other immune cells in patients with MS.

Summary

A systematic review of Zn potential role in the pathogenesis of MS as well as a meta-analysis showing significantly lowered Zn levels in MS patients compared with healthy controls.

Author Contributions

B. M. and F. J. L. designed the project, developed the methodology, and collected the data. B. M. performed the analysis and wrote the first draft of the manuscript while F. J. L. edited the manuscript.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

References

Achiron, A., Gurevich, M., Snir, Y., Segal, E., & Mandel, M. (2007). Zinc-ion binding and cytokine activity regulation pathways predicts outcome in relapsing-remitting multiple sclerosis. *Clinical and Experimental Immunology*, 149, 235–242.

Adamo, A. M., Zago, M. P., Mackenzie, G. G., Aimo, L., Keen, C. L., Keenan, A., … Oteiza, P. I. (2010). The role of zinc in the modulation of neuronal proliferation and apoptosis. *Neurotoxicology Research*, 17(1): 1–14.

Alimonti, A., Ristori, G., Giubilei, F., Stazi, M. A., Pino, A., Visconti, A., … Sancesario, G. (2007). Serum chemical elements and oxidative status in Alzheimer’s disease, Parkinson disease and multiple sclerosis. *Neurotoxicology*, 28, 450–456.
Al-Zubaidi, M. A. (2012). The effect of interferon beta-1b and methylprednisolone treatment on the serum trace elements in Iraqi patients with multiple sclerosis. *Journal of Clinical & Diagnostic Research, 6*, 994–998.

Bar-Or, A., Nuttall, R. K., Duddy, M., Alter, A., Kim, H. J., Ifergan, I.,… Yong, V. W. (2003). Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. *Brain: A Journal of Neurology, 126*, 2738–2749.

Berlet, H. H., Bischoff, H., & Weinhardt, F. (1994). Divalent metals of myelin and their differential binding by myelin basic protein of bovine central nervous system. *Neuroscience Letters, 179*, 75–78.

Borenstein, M., Hedges, L. V., Higgins, J. P. T. and Rothstein, H. R. (2009). Random-Effects Model. In *Introduction to Meta-Analysis* (pp. 69–86). Chichester, UK: John Wiley & Sons, Ltd. doi: 10.1002/9780470743386.ch12.

Briggs, M. H., Briggs, M., & Austin, J. (1971). Effects of steroid pharmaceuticals on plasma zinc. *Nature, 232*, 480–481.

Chandler, S., Coates, R., Gearing, A., Lury, J., Wells, G., Bone, E. (1986). Comparison of zinc contents in human serum and plasma. *Clinica Chimica Acta, 155*, 185–187.

Choi, B. Y., Jang, B. G., Kim, J. H., Seo, J. N., Wu, G., Sohn, M.,… Suh, S. W. (2013). Copper/zinc chelation by clioquinol reduces spinal cord white matter damage and behavioral deficits in a murine MOG-induced multiple sclerosis model. *Neurobiology of Disease, 54*, 382–391.

Compston, A., & Coles, A. (2008). Multiple sclerosis. *Lancet (London, England), 372*, 1502–1517.

Correale, J., & Bassani Molinas Mde, L. (2003). Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS. *Journal of Neuroimmunology, 140*, 198–209.

Dore-Duffy, P., Catalanotto, F., Donaldson, J. O., Ostrom, K. M., & Testa, M. A. (1983). Zinc in multiple sclerosis. *Annals of Neurology, 14*, 450–454.

Fallah, S., Sani, F. V., & Firoozrai, M. (2009). Effect of contraceptive pill on the selenium and zinc status of healthy subjects. *Contraception, 80*, 40–43.

Foley, B., Johnson, S. A., Hackley, B., Smith, J. C. Jr., & Halsted, J. A. (1968). Zinc content of human platelets. *Proceedings of the Society for Experimental Biology and Medicine for Experimental Biology and Medicine (New York, NY), 128*, 265–269.

Foong, J., Rozewicz, L., Chong, W. K., Thompson, A. J., Miller, D. H., Ron, M. A. (2000). A comparison of neuropsychological deficits in primary and secondary progressive multiple sclerosis. *Journal of Neurology, 247*, 97–101.

Forte, G., Visconti, A., Santucci, S., Ghazaryan, A., Figatampana, L., Cannoni, S.,… Ristori, G. (2005). Quantification of chemical elements in blood of patients affected by multiple sclerosis. *Annali dell’Istituto superiore di sanità, 41*, 213–216.

Gellein, K., Skoghol, J. H., Aaseth, J., Thoresen, G. B., Lierhagen, S., Steinnes, E.,… Flaten, T. P. (2008). Trace elements in cerebrospinal fluid and blood from patients with a rare progressive central and peripheral demyelinating disease. *Journal of the Neurological Sciences, 266*, 70–78.

Ghazavi, A., Kianbakht, S., Ghasami, K., & Mosayebi, G. (2012). High copper and low zinc serum levels in Iranian patients with multiple sclerosis: A case control study. *Clinical Laboratory, 58*, 161–164.

Ghoreishi, A., Mohsni, M., Amraei, R., Alizadeh, A. M., & Mazloomzadeh, S. (2015). Investigation the amount of copper, lead, zinc and cadmium levels in serum of Iranian multiple sclerosis patients. *Journal of Chemical and Pharmaceutical Sciences, 8*, 40–45.

Giacoppo, S., Galuppo, M., Calabro, R. S., D’Aleoo, G., Marra, A., Sessa, E.,… Mazzon, E. (2014). Heavy metals and neurodegenerative diseases: An observational study. *Biological Trace Element Research, 161*, 151–160.

Harbige, L. S., Pinto, E., Xiang, M., & Shareif, M. K. (2011). Circulating plasma cytokines, zinc, copper, vitamins A and E in multiple sclerosis patients and healthy controls. *Proceedings of the Nutrition Society, 70*, E36.

Higashi, Y., Segawa, S., Matsuo, T., Nakamura, S., Kikkawa, Y., Nishida, K.,… Nagasawa, K. (2011). Microglial zinc uptake via zinc transporters induces ATP release and the activation of microglia. *Glia, 59*, 1933–1945.

Ho, S. Y., Catalanotto, F. A., Lisak, R. P., & Dore-Duffy, P. (1986). Zinc in multiple sclerosis. II: Correlation with disease activity and elevated plasma membrane-bound zinc in erythrocytes from patients with multiple sclerosis. *Annals of Neurology, 20*, 712–715.

Iyengar, G. V. (1987). Reference values for the concentrations of As, Cd, Co, Cr, Cu, Fe, I, Hg, Mn, Mo, Ni, Pb, Se, and Zn in selected human tissues and body fluids. *Biological Trace Element Research, 12*, 263–295.

Kanesaka, T., Mori, M., Hattori, T., Oki, T., & Kuwabara, S. (2006). Serum metal matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis. *Journal of Neurology. Neurosurgery, and Psychiatry, 77*, 185–188.

Kapaki, E., Segditsa, J., & Papageorgiou, C. (1989). Zinc, copper and magnesium concentration in serum and CSF of patients with neurological disorders. *Acta Neurologica Scandinavica, 79*, 373–378.

Kasperek, K., Kiem, J., Iyengar, G. V., & Feinendegen, L. E. (1981). Concentration differences between serum and plasma of the elements cobalt, iron, mercury, rubidium, selenium and zinc determined by neutron activation analysis. *The Science of the Total Environment, 17*, 133–143.

Kazmierczak, K., Malukiewicz, G., Lesiewska-Junk, H., Laudencnka, A., Szady-Grad, M., Klawe, J.,… Nowicki, K. (2014). Blood plasma levels of microelements in patients with history of optic neuritis. *Current Eye Research, 39*, 93–98.

Killerich, S., Christensen, M. S., Naestoft, J., & Christiansen, C. (1980). Determination of zinc in serum and urine by atomic absorption spectrophotometry; relationship between serum levels of zinc and proteins in 104 normal subjects. *Clinica Chimica Acta, 105*, 231–239.

Killerich, S., Sanvig, M., Naestoft, C. J., & Christiansen, C. (1981). Serum and plasma zinc concentrations with special reference to standardized sampling procedure and protein status. *Clinica Chimica Acta, 114*, 117–121.

Kitamura, H., Morikawa, H., Kamon, H., Iguchi, M., Hijo, S., Fukada, T.,… Hirano, T. (2006). Toll-like receptor-mediated...
regulation of zinc homeostasis influences dendritic cell function. *Nature Immunology*, 7, 971–977.

Kosman, D. J., & Henkin, R. I. (1979). Plasma and serum zinc concentrations. *Lancet (London, England)*, 1, 1410.

Larsen, P. H., Wells, J. E., Stallcup, W. B., Opdenakker, G., & Yong, V. V. (2003). Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. *The Journal of Neuroscience*, 23, 11127–11135.

Lassmann, H., Bruck, W., & Lucchinetti, C. (2001). Heterogeneity of multiple sclerosis pathogenesis: Implications for diagnosis and therapy. *Trends in Molecular Medicine*, 7, 115–121.

Leppert, D., Waubant, E., Galardy, R., Bunnett, N. W., & Hauser, S. L. (1995). T cell gelatinases mediate basement membrane transmigration in vitro. *Journal of Immunology (Baltimore, Md: 1950)*, 154, 4379–4389.

Linke, E., Winnefeld, K., & Dawczynski, H. (1977). Ion concentration in the cerebrospinal fluid in multiple sclerosis. *Psychiatry, Neurologie, und Medizinische Psychologie*, 7, 1–8.

Liu, G. M., Trojano, M., Fanelli, M., Avolio, C., Fasano, A., Livrea, P., & Riccio, P. (2002). Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: Implication for pathogenesis. *Multiple Sclerosis (Houndmills, Basingstoke, England)*, 8, 222–228.

Markowitz, M. E., Rosen, J. F., & Mizuuchi, M. (1985). Circadian variations in serum zinc (Zn) concentrations: Correlation with blood ionized calcium, serum total calcium and phosphate in humans. *The American Journal of Clinical Nutrition*, 41, 689–696.

Masoud, S. A., & Fakharian, E. (2007). Assessment of serum magnesium, copper, and zinc levels in multiple sclerosis (MS) patients. *Iranian Journal of Psychiatry and Behavioral Sciences*, 1, 38–42.

Mauch, E., Gebhardt, A., Stiefl, T., Rauer, S., Wagner, U., Laufen, H., & Kornhuber, H. H. (1995). Trace metals in multiple sclerosis. *Neurology Psychiatry and Brain Research*, 1, 149–154.

Melo, T. M., Larsen, C., White, L. R., Aasly, J., Sjøbakk, T. E., Flaten, T. P., & Syversen, T. (2003). Manganese, copper, and zinc in cerebrospinal fluid from patients with multiple sclerosis. *Biological Trace Element Research*, 93(1–3): 1–8.

Murphy, G., & Nagase, H. (2008). Progress in matrix metalloproteinase research. *Molecular Aspects of Medicine*, 29, 290–308.

Nasrabadi, M. N., Forghani, D., Shahabi, I., & Shirini, R. (2012). Determination of trace elements in blood samples of patients affected by multiple sclerosis from Iran by neutron activation analysis. *Journal of Radioanalytical and Nuclear Chemistry*, 289, 479–482.

Palm, R., & Hallmans, G. (1982). Zinc and copper in multiple sclerosis. *Journal of Neurology, Neurosurgery, and Psychiatry*, 45, 691–698.

Patsopoulos, N. A., Barcellos, L. F., Hintzen, R. Q., Schaefer, C., van Duijn, C. M., Noble, J. A., &IMSgc, A. (2013). Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects. *PLoS Genet*, 9, e1003926.

Ram, M., Sherer, Y., & Shoenveld, Y. (2006). Matrix metalloproteinase-9 and autoimmune diseases. *Journal of Clinical Immunology*, 26, 299–307.

Rea, I. M. (1989). Sex and age changes in serum zinc levels. *Nutrition Research*, 9, 121–125.

Rieder, H. P., Schoettli, G., & Seiler, H. (1983). Trace elements in whole blood of multiple sclerosis. *European Neurology*, 22, 85–92.

Rink, L., & Gabriel, P. (2000). Zinc and the immune system. *The Proceedings of the Nutrition Society*, 59, 541–552.

Sadovnick, A. D., & Ebers, G. C. (1993). Epidemiology of multiple sclerosis: A critical overview. *The Canadian Journal of Neurological Sciences*, 20, 17–29.

Salari, S., Khomand, P., Arasteh, M., Yousefzamani, B., & Hassanzadeh, K. (2015). Zinc sulphate: A reasonable choice for depression management in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial. *Pharmacological Reports*, 67, 606–609.

Scott, B. J., & Bradwell, A. R. (1983). Identification of the serum binding proteins for iron, zinc, cadmium, nickel, and calcium. *Clinical Chemistry*, 29, 629–633.

Sedighi, B., Ebrahimi, H. A., Haghdoot, A. A., & Abotorabi, M. (2013). Comparison of serum levels of copper and zinc among multiple sclerosis patients and control group. *Iranian Journal of Neurology*, 12, 125–128.

Smith, D. K., Feldman, E. B., & Feldman, D. S. (1989). Trace element status in multiple sclerosis. *The American Journal of Clinical Nutrition*, 50, 136–140.

Stoye, D., Schubert, C., Goihl, A., Guttek, K., Reinhold, A., Brocke, S., & Reinhold, D. (2012). Zinc aspartate suppresses T cell activation in vitro and relapsing experimental autoimmune encephalomyelitis in SJL/J mice. *Biometals: An International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine*, 25, 529–539.

Tanaka, Y. (1989). A study on the role of zinc on the immune response and body metabolism—a contribution of trace elements. *The Kobe Journal of Medical Sciences*, 35, 299–309.

Vallee, B. L., & Falchuk, K. H. (1993). The biochemical basis of zinc physiology. *Physiological Reviews*, 73, 79–118.

Wollock, L. M., King, J. C., Hambidge, K. M., English-Westcott, J. E., & Pritts, J. (1993). Meal-induced changes in plasma, erythrocyte, and urinary zinc concentrations in adult women. *The American Journal of Clinical Nutrition*, 58, 695–701.

Wieser, M. E., Holden, N., Coplen, T. B., Böhike, J. K., Berglund, M., Brand, W. A., Zhu, X-K. (2013). Atomic weights of the elements 2011 (IUPAC Technical Report). In *Pure and Applied Chemistry*, 1047.

Weisemann, K., Asboe-Hansen, G., Secher, L., Pedersen, E., & Hansen, H. J. (1982). Plasma zinc levels in multiple sclerosis. *Metabolic, Pediatric, and Systemic Ophthalmology*, 6, 137–139.

Williams, C. M., Lines, C. M., & McKay, E. C. (1988). Iron and zinc status in multiple sclerosis patients with pressure sores. *European Journal of Clinical Nutrition*, 42, 321–328.

Wong, E. K. Jr., Enomoto, H., Leopold, I. H., Fleischer, E. B., Schoon, D. V., Fender, D., Nudelman, K. (1980). Plasma zinc levels in multiple sclerosis. *Metabolic and Pediatric Ophthalmology*, 4, 3–8.

Yokoyama, M., Koh, J., & Choi, D. W. (1986). Brief exposure to zinc is toxic to cortical neurons. *Neuroscience Letters*, 71, 351–355.